Form 4: Exelixis Executive Amy C. Peterson Reports Acquisition of 82,121 Shares of Common Stock

Amy C. Peterson, EVP of Product Development & Medical Affairs and CMO at Exelixis, Inc., reports the acquisition of 82,121 shares of common stock through restricted stock units.

Summary

• Amy C. Peterson, an executive at Exelixis, Inc., filed a Form 4 with the SEC.
• The report details the acquisition of 82,121 shares of Exelixis common stock on February 23, 2024.
• These shares were acquired through the vesting of restricted stock units (RSUs).
• The RSUs were granted under the Exelixis, Inc. 2017 Equity Incentive Plan.
• The RSUs vest in four equal installments, starting on May 15, 2025, and annually thereafter until fully vested.
• Following the transaction, Peterson beneficially owns 322,121 shares of Exelixis common stock, including those issuable upon vesting of RSUs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence from the executive in the company's stock.

Positives

• The acquisition of shares by an executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency regarding the alignment of executive interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages including restricted stock units are a standard practice among publicly traded companies, particularly in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize equity-based compensation to incentivize and retain key personnel.
• The vesting schedules and terms of these grants are typically benchmarked against industry peers to ensure competitiveness.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns executive interests with company performance.

Key Dates